Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
about
DNA adducts in humans as biomarkers of exposure to environmental and occupational carcinogensBiologic markers in risk assessment for environmental carcinogensPersistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individualsLinking DNA adduct formation and human cancer risk in chemical carcinogenesis.Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independentAlkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II).Human DNA adduct measurements: state of the artDNA adducts as exposure biomarkers and indicators of cancer riskPlatinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapyThe potential usefulness of biological markers in risk assessmentCisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitroPlatinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy.Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.Chemotherapy-induced peripheral neurotoxicity.Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer modelRelationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumoursNucleotide excision repair and anti-cancer chemotherapyPlatinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapyPhase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancerOxaliplatin-DNA adduct formation in white blood cells of cancer patientsPersonalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopyDNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins.The influence of Cisplatin on the gas-phase dissociation of oligonucleotides studied by electrospray ionization tandem mass spectrometry.Perspectives in the field of drug metabolism.Principles of genetic toxicology.The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells.Analysis of Vgamma/Jbeta trans-rearrangements in paediatric patients undergoing chemotherapy
P2860
Q23920037-618AD839-DF19-40B3-91B0-6CCC34498202Q23922550-2B6D05C5-284B-4584-8227-89E918660C18Q28305738-4BD761EF-416F-4A2F-93F4-2C0D1B4FEB55Q30249312-EC1F6A42-96CE-414B-BC3C-A0C497FE8BF4Q33826103-00B27007-5A24-4752-8C3F-AD32DE7F2553Q33908498-EA85F907-A7BC-45A8-8D1D-4D2207BA03EAQ34368410-31A9AD19-3B9C-4314-A8E9-C72B1B35E856Q34637114-836FCBA1-56AC-48DA-BE8B-5B43E982A049Q34638964-02D7D99B-06A4-47A0-928C-03B4FFE5C59EQ34640816-D38E2133-010F-44FB-93AF-802308F209DCQ34660101-0539A025-AA93-4FC8-ACA7-22EEAB64EDC3Q34843715-7FDA0147-13F6-46FA-9EE4-475531656893Q35031455-6A644ED5-426B-4D71-A4F7-FDE4F054833AQ35818950-F35C9F3D-F267-411E-A73C-4EAFB4149691Q35925635-38881D2F-1F6C-48DB-BB82-A7B7B922124FQ36073949-449104AF-0973-48BD-B2E3-D1AB9A1CB5CAQ36135407-88638000-A285-4CD6-91EB-A9925CDBEDC3Q36254803-A1163AAB-1022-427A-9964-BA9164836459Q36431475-E156D290-B840-4BD6-B585-998A399B3627Q36597012-52632C97-1E0C-4DFF-A71F-06E2F7FDDABFQ36740632-A45A5F4C-2402-47DD-B5F8-54A74A055B46Q36817080-695AE809-79F7-4FCF-8E4E-62B7872F2C20Q36875580-205454F3-A712-46B3-948C-14CB3A365AE9Q37736567-A77D19ED-3E52-46B7-80EB-9272FB359C07Q38297625-6EDEA97F-F3D0-4960-B473-537D88914ABDQ38356787-D700B065-062E-4427-84AA-DDBBEB556161Q40632141-7EBE9FB1-BFD5-4A44-9810-7656550774CDQ41228050-7E493E3C-2301-4546-9021-9C6E732033E9Q41916312-C5AEB621-9E05-4857-8DD2-C051C392459BQ57502479-ED100050-A5E8-4FA8-A4E7-B5C7EB5CC17B
P2860
Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
description
1986 nî lūn-bûn
@nan
1986 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1986 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
name
Quantitation of cis-diamminedi ...... eiving cisplatin chemotherapy.
@ast
Quantitation of cis-diamminedi ...... eiving cisplatin chemotherapy.
@en
Quantitation of cis-diamminedichloroplatinum II
@nl
type
label
Quantitation of cis-diamminedi ...... eiving cisplatin chemotherapy.
@ast
Quantitation of cis-diamminedi ...... eiving cisplatin chemotherapy.
@en
Quantitation of cis-diamminedichloroplatinum II
@nl
prefLabel
Quantitation of cis-diamminedi ...... eiving cisplatin chemotherapy.
@ast
Quantitation of cis-diamminedi ...... eiving cisplatin chemotherapy.
@en
Quantitation of cis-diamminedichloroplatinum II
@nl
P2093
P2860
P356
P1476
Quantitation of cis-diamminedi ...... eiving cisplatin chemotherapy.
@en
P2093
P2860
P304
P356
10.1172/JCI112335
P407
P577
1986-02-01T00:00:00Z